Vultaggio, Alessandra
Aliani, Maria
Altieri, Elena
Bracciale, Pietro
Brussino, Luisa
Caiaffa, Maria Filomena
Cameli, Paolo
Canonica, Giorgio Walter
Caruso, Cristiano
Centanni, Stefano
D’Amato, Maria
De Michele, Fausto
Del Giacco, Stefano
Di Marco, Fabiano
Menzella, Francesco
Pelaia, Girolamo
Rogliani, Paola
Romagnoli, Micaela
Schino, Pietro
Senna, Gianenrico
Benci, Marco
Boarino, Silvia
Schroeder, Jan Walter
Article History
Received: 6 March 2023
Accepted: 28 April 2023
First Online: 20 May 2023
Declarations
:
: This study was conducted in accordance with the ethical principles laid down in the Declaration of Helsinki and to the regulations and guidelines governing medical practice and ethics in Italy. All patients provided informed consent before being enrolled in the study and signed additional and amended study informed consent and privacy forms for the extended period of observation. Ethical approval was provided by the ethics committees/institutional review boards at each participating site.
: Not applicable.
: AV declares fees as speaker/lecturer by AstraZeneca, Chiesi Farmaceutici, GSK, Novartis, Sanofi; MA has nothing to declare; EA has nothing to declare; PB has nothing to declare; LB has nothing to declare; MFC has nothing to declare; PC reports having received in the last 3 years research grants and fees as speaker from AstraZeneca-MedImmune, Guidotti-Malesci and GlaxoSmithKline; GWC reports having received in the last 3 years research grants as well as lecture or advisory board fees from A. Menarini, Allergy—Therapeutics, AstraZeneca-MedImmune, Boehringer Ingelheim, Chiesi, Faes, Genentech, Guidotti-Malesci, GlaxoSmithKline, HAL Allergy, Novartis, Sanofi-Aventis, Sanofi-Genzyme/Regeneron, Stallergenes-Greer, Thermo Fisher, Valeas, Vifor Pharma; CC has nothing to declare; SC declares grants and/or personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Glaxo Smith Kline, Guidotti, Menarini, Novartis, Valeas; MDA has nothing to declare; FDMa has received lectures fees at national and international meetings and consultancy fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Dompé, Guidotti/Malesci, GlaxoSmithKline, Menarini, Novartis, and Zambon; SDG received grants and/or personal fees from AstraZeneca, Chiesi, Glaxo Smith Kline, Menarini, Novartis, Sanofi; FDMi has nothing to declare; FM declares research funding as Principal investigator by AstraZeneca, Chiesi Farmaceutici, Novartis, Sanofi; fees as speaker/lecturer by AstraZeneca, Chiesi Farmaceutici, GlaxoSmithKline, Novartis, Sanofi; GP has received lecture fees and consultancy fees from AlfaSigma, AstraZeneca, Chiesi, GlaxoSmithKline, Guidotti-Malesci, Menarini, Mundipharma, Novartis, Sanofi, Zambon; PR has participated as a lecturer, speaker, and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis, her department has received funding from Almirall, Boehringer Ingelheim, Chiesi, Novartis, and Zambon; MR declares grants and personal fees from Boehringer Ingelheim, Roche, AstraZeneca, Novartis, Chiesi, GSK, Menarini, Guidotti, AlfaSigma, Zambon; PS has nothing to declare; GS has nothing to declare; MB and SB are AstraZeneca employees; JWS has nothing to declare.